CorestemChemon Partners with ATG Lifetech to Expand Organoid and Transcriptomics Capabilities

CorestemChemon; ATG Lifetech; organoids; transcriptomics; preclinical CRO; drug discovery; predictive analytics; tumorigenicity; FDA/EMA regulatory pathways; liver organoids; heart organoids; blood-brain barrier models

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

FDA Investigates Patient Deaths Linked to Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy

FDA; Sarepta; Elevidys; Duchenne muscular dystrophy; gene therapy; patient deaths; acute liver failure; liver toxicity; regulatory investigation; non-ambulatory patients

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill

Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration

Fauna Brain; agentic AI; drug discovery; comparative genomics; Lilly collaboration; multi-agent system; pharmaceutical research; AI platform